Dermira Inc. (NASDAQ:DERM) CFO Andrew Guggenhime sold 10,900 shares of Dermira stock in a transaction that occurred on Tuesday, October 11th. The stock was sold at an average price of $34.34, for a total value of $374,306.00. Following the completion of the transaction, the chief financial officer now owns 16,016 shares of the company’s stock, valued at approximately $549,989.44. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Andrew Guggenhime also recently made the following trade(s):

  • On Monday, September 19th, Andrew Guggenhime sold 15,000 shares of Dermira stock. The stock was sold at an average price of $35.01, for a total value of $525,150.00.
  • On Monday, September 12th, Andrew Guggenhime sold 10,000 shares of Dermira stock. The stock was sold at an average price of $32.53, for a total value of $325,300.00.
  • On Thursday, August 11th, Andrew Guggenhime sold 10,000 shares of Dermira stock. The stock was sold at an average price of $31.02, for a total value of $310,200.00.

Dermira Inc. (NASDAQ:DERM) opened at 32.41 on Tuesday. Dermira Inc. has a 12-month low of $17.42 and a 12-month high of $36.16. The stock’s market cap is $1.15 billion. The company’s 50-day moving average price is $33.52 and its 200-day moving average price is $30.24.

Dermira (NASDAQ:DERM) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.03. On average, equities analysts expect that Dermira Inc. will post ($3.46) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Several institutional investors have recently made changes to their positions in DERM. Cupps Capital Management LLC purchased a new position in shares of Dermira during the third quarter worth approximately $1,320,000. Schwab Charles Investment Management Inc. boosted its position in shares of Dermira by 30.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 62,986 shares of the biopharmaceutical company’s stock worth $1,843,000 after buying an additional 14,566 shares during the last quarter. American Century Companies Inc. purchased a new position in shares of Dermira during the second quarter worth approximately $1,352,000. Metropolitan Life Insurance Co. NY boosted its position in shares of Dermira by 25.5% in the second quarter. Metropolitan Life Insurance Co. NY now owns 15,819 shares of the biopharmaceutical company’s stock worth $463,000 after buying an additional 3,210 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its position in shares of Dermira by 66.5% in the second quarter. Point72 Asset Management L.P. now owns 127,700 shares of the biopharmaceutical company’s stock worth $3,735,000 after buying an additional 51,000 shares during the last quarter. 82.57% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have recently commented on DERM shares. Needham & Company LLC reiterated a “positive” rating and issued a $46.00 target price on shares of Dermira in a report on Monday, October 3rd. Leerink Swann restated a “buy” rating on shares of Dermira in a report on Wednesday, October 5th. Finally, Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a report on Wednesday, June 22nd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $41.00.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

5 Day Chart for NASDAQ:DERM

Receive News & Stock Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related stocks with our FREE daily email newsletter.